Last10K.com

Myovant Sciences Ltd. (MYOV) SEC Filing 10-K Annual Report for the fiscal year ending Thursday, March 31, 2022

SEC Filings

Myovant Sciences Ltd.

CIK: 1679082 Ticker: MYOV

Exhibit 99.1



myovant16.jpg
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 million
European Commission approval of ORGOVYX® as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe in April 2022
Announced exclusive license agreement with Accord Healthcare, Ltd. (Accord) to commercialize ORGOVYX in Europe; total deal value up to $140.5 million, inclusive of upfront payment of $50.0 million, plus tiered royalties
Net product revenue from U.S. sales of ORGOVYX of $83.0 million in fiscal year 2021; fourth fiscal quarter 2021 net product revenues of $29.4 million with sequential quarterly demand volume growth of 18%
Net product revenue from U.S. sales of MYFEMBREE® of $6.4 million in fiscal year 2021; fourth fiscal quarter 2021 net product revenues of $2.2 million; nearly doubling of MYFEMBREE demand volume quarter-over-quarter offset by gross-to-net seasonality
ORGOVYX cumulative patients estimated at 14,500 through March 2022
MYFEMBREE is now the number one prescribed FDA-approved gonadotropin-releasing hormone (GnRH) antagonist therapy for the treatment of uterine fibroids for new patients; 59% new-to-brand share in March 2022
Prescription Drug User Fee Act (PDUFA) goal date for MYFEMBREE for the management of moderate to severe pain associated with endometriosis extended by FDA to August 6, 2022
SPIRIT long-term extension study demonstrated consistent efficacy and safety profile of MYFEMBREE over two years in women with endometriosis-associated pain
Myovant remains well-capitalized with cash, cash equivalents, and marketable securities of $434.2 million as of March 31, 2022
BASEL, Switzerland, May 10, 2022 -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the fourth fiscal quarter and fiscal year ended March 31, 2022 and provided other corporate updates.
“Fiscal year 2021 was a transformative year for Myovant as we expanded ORGOVYX utilization in the U.S. and successfully launched MYFEMBREE, finishing the year with another quarter of strong demand growth. Our recent approval of ORGOVYX in Europe and partnership with Accord, coupled with our prior approval of RYEQO, will enable more patients than ever to have access to these meaningful and differentiated medicines,” said David Marek, Chief Executive Officer of Myovant Sciences, Inc. Mr. Marek added, “Our strong commercial momentum, advancement of our lifecycle and business development strategies, and our financial strength position Myovant for another exciting year in fiscal year 2022.”



The following information was filed by Myovant Sciences Ltd. (MYOV) on Tuesday, May 10, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Myovant Sciences Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Myovant Sciences Ltd..

Continue

Assess how Myovant Sciences Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Myovant Sciences Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Legal
Revenue
Mgmt Change
Other
Filter by Subcategory:
All
Cash Flow
Expense
Product
Geography
Shares
Other
Inside Myovant Sciences Ltd.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Consolidated Statements Of Shareholders' Deficit
Consolidated Statements Of Shareholders' Equity (Deficit) (Parenthetical)
Certain Balance Sheet Components
Certain Balance Sheet Components (Tables)
Certain Balance Sheet Components - Accrued Expenses And Other Current Liabilities (Details)
Certain Balance Sheet Components - Inventories (Details)
Collaboration And License Agreements
Collaboration And License Agreements (Tables)
Collaboration And License Agreements - Contract Balances (Details)
Collaboration And License Agreements - Narrative (Details)
Collaboration And License Agreements - Remaining Transaction Price (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Defined Contribution Plan
Defined Contribution Plan (Details)
Description Of Business
Description Of Business (Details)
Extinguishment Of Debt
Extinguishment Of Debt (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details)
Fair Value Measurements - Fair Value Of Share-Based Compensation Liabilities (Details)
Fair Value Measurements - Narrative (Details)
Fair Value Measurements - Summary Of Changes In Fair Value Of Level 3 Valuation (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Deferred Taxes (Details)
Income Taxes - Effective Income Tax Reconciliation (Details)
Income Taxes - Loss Before Income Taxes And Related Tax Benefit (Details)
Income Taxes - Narrative (Details)
Income Taxes - Unrecognized Tax Benefit (Details)
Leases
Leases (Tables)
Leases - Narrative (Details)
Leases - Operating Lease Expense (Details)
Leases - Operating Lease Liability Maturities (Details)
Leases - Operating Lease Right Of Use Assets And Liabilities (Details)
Related Party Disclosures (Tables)
Related Party Transactions
Related Party Transactions (Annual Maturities Of Amounts Outstanding) (Details)
Related Party Transactions (Narrative) (Details)
Revenue Components
Revenue Components (Tables)
Revenue Components - Disaggregation Of Revenue (Details)
Revenue Components - Narrative (Details)
Revenue Components - Schedule Of Discounts And Allowances (Details)
Revenue Components - Schedule Of Product Revenue By Geography (Details)
Revenue Components - Schedule Of Reserves As Balance Sheet Components (Details)
Share-Based Compensation
Share-Based Compensation (Additional Information Regarding Options) (Details)
Share-Based Compensation (Narrative) (Details)
Share-Based Compensation (Performance Stock Units) (Details)
Share-Based Compensation (Restricted Share Awards And Restricted Stock Units Activity) (Details)
Share-Based Compensation (Schedule Of Fair Value Assumptions For Stock Options) (Details)
Share-Based Compensation (Share-Based Compensation Expense) (Details)
Share-Based Compensation (Summary Of Option Activity) (Details)
Share-Based Compensation (Tables)
Shareholders' Deficit
Shareholders' Deficit (Details)
Subsequent Event
Subsequent Event (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities (Details)
Ticker: MYOV
CIK: 1679082
Form Type: 10-K Annual Report
Accession Number: 0001679082-22-000071
Submitted to the SEC: Wed May 11 2022 9:02:47 AM EST
Accepted by the SEC: Wed May 11 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/myov/0001679082-22-000071.htm